Things are happening fast at BridgeBio as it plugs away at the launch of blockbuster-in-waiting Attruby and prepares to potentially introduce three new drugs to the market within the next 12 months. To help the 11-year-old California biotech ramp up for the commercial surge, Sixth Street and HealthCare Royalty have agreed to invest up to $1 billion in newly issued convertible preferred equity into the company. While BridgeBio declared that the investment is designed to support its current and upcoming launches, analysts from Leerink speculated that the company could be thinking of M&A.
Read the full article: BridgeBio Attracts $1B in Equity for New Launches, but Analyst Smells M&A ‘Dry Powder’ //
Source: https://www.fiercepharma.com/pharma/bridgebio-attracts-1b-equity-financing-launches-attruby-potential-new-products